Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.
about
Recent advances in understanding apicomplexan parasitesDesigning modulators of monoamine transporters using virtual screening techniquesThe malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugsAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkNext-generation antimicrobials: from chemical biology to first-in-class drugsOpen Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondMuddled mechanisms: recent progress towards antimalarial target identificationAlternatives to currently used antimalarial drugs: in search of a magic bulletBiochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetaseA New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug DiscoveryEvidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria ParasitesNa+ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of Plasmodium falciparumBiological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathwayComparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitorA high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytesThe Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic ScreensIn vitro adaptation of Plasmodium falciparum reveal variations in cultivability.Luciferase-Based, High-Throughput Assay for Screening and Profiling Transmission-Blocking Compounds against Plasmodium falciparum Gametocytes.A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050.SC83288 is a clinical development candidate for the treatment of severe malaria.Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance.The Candidate Antimalarial Drug MMV665909 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with Quinoline-Derived Antimalarials.Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.Antimalarial Drug Resistance: A Threat to Malaria Elimination.A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle.A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission.A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi.Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery.Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance.Diverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasis.Biochemical characterization and chemical inhibition of PfATP4-associated Na-ATPase activity in membranesEvaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in VitroTackling resistance: emerging antimalarials and new parasite targets in the era of eliminationCell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated AntimalarialsDevelopment of medicines for the control and elimination of malaria
P2860
Q26747055-4C3FF4CB-6E9D-4F5C-AC7B-B34A9465722CQ26781605-8BE6A8D9-E98B-442C-897B-EDDC86AC0ACFQ26781634-1E2D1D08-FD0C-47E2-BE44-7B50F2194AEBQ26799713-3E628543-EF1E-4B87-972B-ED0252AA5339Q26799749-BC7B2930-ED44-4D30-8A77-552380215343Q26883657-46708259-24ED-4EBC-8339-8EA0CDFDD575Q27826351-B48779F1-D7AE-4D5A-B1F1-259745522AC8Q28066421-F180B415-44B9-4567-8674-A99ECF263ED2Q28070398-8F6763B1-387C-4AA3-BEAB-94A3F5E4437EQ28468285-1102BEE3-F50A-48A8-B16A-56EECF0251B0Q28547546-91432F34-5AED-46DA-98D9-41C99FF69CC9Q28551519-3549987F-4E8A-4FBA-82FD-17878109F37FQ28552457-9E504FA4-F21E-4168-A847-BD4ED70ED5A2Q28821118-4506593D-EA41-4360-B830-BBC2D45DB78DQ28830547-85888D2B-FD8C-452B-84AA-7BC7095D7E96Q28831140-3B96F32E-10AA-49A7-B4F6-48B4EDEA0B00Q30042965-B3EC31C0-33E6-467E-9E4A-313B6B957F2CQ30277705-42F4E869-4D91-441D-A1F2-23266006AED0Q35898587-CA0167DF-EF0A-447B-A24D-C89E7315A1CAQ36365291-BF8A88E9-AF41-48C4-AE12-364DB3003E2CQ36644774-4DF8C85A-2952-424A-85B1-7F066028AF64Q37622611-72D01B47-C2B3-4FEA-B8C5-15F623E24A27Q38399949-EEE5E2C6-1659-44EE-B47B-5099DE82BFD7Q38708103-7BF6C878-B6EB-4965-8B56-FF5D9ABB9124Q38782578-993AD91D-A00A-438D-B2D6-DBC707B9BDE9Q39176615-E283228F-DC66-44A0-AF0B-C5F6A3F3C6ACQ39314820-A64D9F2B-9446-445C-BE70-A7CDC22F91DFQ40065688-60BBCD0C-15E1-4295-87BF-E05D4FB41C48Q40106428-C96B5319-3A0E-4373-A4B1-8F5566903C24Q47096821-EA9E70C0-1E41-42DE-A32A-5AFE639BE6F2Q48018710-6D3C24D8-1CDA-436A-9CB5-6592694F1A22Q49927350-89902FA7-622A-4B15-B586-4A5EF17F2FB9Q49959001-D7C6DCDD-E3B8-410E-9109-9B9480801531Q55334152-B8322499-D382-4273-9599-3A0763EEEC79Q56341251-52A3C5C3-314F-4F55-B2F5-049087681198Q56344152-13D312D1-16DA-4913-956B-587313545B32Q56350408-949ABA80-0D7E-419C-BD1B-F0E489CD757EQ56379943-9DEBBCDC-FC56-4005-8243-01A4764DD10CQ57019124-D45A74AA-34CC-43B4-AA68-F8B1BC7DB40B
P2860
Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pyrazoleamide compounds are po ...... hrocytic Plasmodium falciparum
@nl
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@ast
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@en
type
label
Pyrazoleamide compounds are po ...... hrocytic Plasmodium falciparum
@nl
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@ast
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@en
prefLabel
Pyrazoleamide compounds are po ...... hrocytic Plasmodium falciparum
@nl
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@ast
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@en
P2093
P2860
P50
P921
P3181
P356
P1476
Pyrazoleamide compounds are po ...... rocytic Plasmodium falciparum.
@en
P2093
Advait Nagle
Akhil B Vaidya
Arnab Chatterjee
Boni F Sebayang
Erkang Fan
Francisco Javier Gamo
Grennady Wirjanata
Iñigo Angulo-Barturen
Joanne M Morrisey
Jutta Marfurt
P2860
P2888
P3181
P356
10.1038/NCOMMS6521
P407
P50
P577
2014-11-25T00:00:00Z
P5875
P6179
1008614784